knowledge -WSS

knowledge

author：explore 2025-09-29 13:30:56 - browse：9833

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Doctors find melanoma drugs effective against rare brain cancer

knowledge

WSS

New brain studies show LSD's effects on the brain in full color

Think you might have Covid

In early work, researchers turn to CRISPR to treat Alzheimer's

Listen: Wegovy in the brain & pivotal Alzheimer's data

How digital therapeutics firms are pivoting after Pear's bankruptcy

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

focus

knowledge

focus

Anesthesiologist group: stop taking Ozempic before surgery

The surgeon had a dilemma only a Nazi medical text could resolve

Virginia high school admissions case could be legal follow

At Orexo, a ‘turning point’ for everything but digital health

Dobbs anniversary: the lost opportunity of abortion as health care

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Test for long Covid? Researchers find new clue in blood samples

How one medical school became remarkably diverse

Prior authorization will have to move faster under new Biden rule

focus

STAT Virtual Event: The State of Biosimilars: What to Watch

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

AI generated plenty of interest at JPM but not a lot of trust

Copay coupons to count toward deductibles, after Biden court move

Test for long Covid? Researchers find new clue in blood samples

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

leisure time

hotspot

knowledge

hotspot